(DHR) Danaher - Ratings and Ratios
Bioprocessing, Mass Spectrometers, Microscopes, Diagnostics, Centrifuges
Dividends
| Dividend Yield | 0.54% |
| Yield on Cost 5y | 0.63% |
| Yield CAGR 5y | 10.67% |
| Payout Consistency | 89.4% |
| Payout Ratio | 18.4% |
| Risk via 10d forecast | |
|---|---|
| Volatility | 25.9% |
| Value at Risk 5%th | 39.3% |
| Relative Tail Risk | -7.90% |
| Reward TTM | |
|---|---|
| Sharpe Ratio | -0.08 |
| Alpha | -19.30 |
| CAGR/Max DD | -0.03 |
| Character TTM | |
|---|---|
| Hurst Exponent | 0.378 |
| Beta | 0.895 |
| Beta Downside | 0.910 |
| Drawdowns 3y | |
|---|---|
| Max DD | 37.57% |
| Mean DD | 13.73% |
| Median DD | 11.55% |
Description: DHR Danaher December 02, 2025
Danaher Corporation (NYSE:DHR) is a diversified industrial and life-sciences company that designs, manufactures, and markets professional, medical, research, and industrial products worldwide, with major operations in the United States, China, and other international markets. It is organized into three reporting segments-Biotechnology, Life Sciences, and Diagnostics-each focused on high-growth, technology-intensive solutions for therapeutic development, analytical instrumentation, and clinical testing.
The Biotechnology segment supplies bioprocessing platforms, single-use hardware, chromatography resins, and related services that enable the rapid development and large-scale manufacturing of biologic drugs. The Life Sciences segment offers a broad portfolio of instruments and consumables-including mass spectrometers, flow cytometers, genomics tools, and laboratory automation-under well-known brands such as Beckman Coulter, Leica Microsystems, and SCIEX. The Diagnostics segment provides clinical chemistry, immunoassay, hematology, and microbiology systems and reagents for hospitals, reference labs, and point-of-care settings.
Key recent data points: Danaher reported FY 2023 revenue of **$30.5 billion**, with an operating margin of **~20 %**, driven largely by double-digit growth in its Biotechnology and Diagnostics businesses. The company’s exposure to the expanding biologics market (global biologics sales are projected to exceed $500 billion by 2028) and the shift toward decentralized diagnostic testing are primary macro-economic tailwinds. Danaher’s disciplined acquisition strategy-exemplified by the 2022 purchase of Cytiva’s bioprocessing assets-continues to augment its addressable market and cross-selling opportunities.
For a deeper quantitative assessment, you might explore Danaher’s metrics on ValueRay’s platform.
Piotroski VR‑10 (Strict, 0-10) 7.0
| Net Income (3.50b TTM) > 0 and > 6% of Revenue (6% = 1.46b TTM) |
| FCFTA 0.06 (>2.0%) and ΔFCFTA 0.06pp (YES ≥ +1.0pp, WARN ≥ +0.5pp) |
| NWC/Revenue 13.52% (prev 11.46%; Δ 2.06pp) (YES ≤20% & Δ≤-1pp; WARN ≤25% & Δ≤0 oder ≤40% & Δ≤-3pp) |
| CFO/TA 0.08 (>3.0%) and CFO 6.32b > Net Income 3.50b (YES >=105%, WARN >=100%) |
| Net Debt (15.33b) to EBITDA (6.87b) ratio: 2.23 <= 3.0 (WARN <= 3.5) |
| Current Ratio 1.52 (target 1.5–3.0; WARN 1.2–<1.5 or >3.0–5.0; CFO/TA gate active) |
| Outstanding Shares last Quarter (713.7m) change vs 12m ago -2.15% (target <= -2.0% for YES) |
| Gross Margin 61.37% (prev 59.37%; Δ 2.01pp) >=18% & Δ>=+0.5pp (WARN >=15% & Δ>=0) |
| Asset Turnover 30.24% (prev 29.45%; Δ 0.79pp) >=50% & Δ>=+2pp (WARN >=35% & Δ>=0) |
| Interest Coverage Ratio 16.41 (EBITDA TTM 6.87b / Interest Expense TTM 271.0m) >= 6 (WARN >= 3) |
Altman Z'' 4.17
| (A) 0.04 = (Total Current Assets 9.61b - Total Current Liabilities 6.32b) / Total Assets 79.90b |
| (B) 0.57 = Retained Earnings (Balance) 45.92b / Total Assets 79.90b |
| (C) 0.06 = EBIT TTM 4.45b / Avg Total Assets 80.26b |
| (D) 1.57 = Book Value of Equity 45.34b / Total Liabilities 28.83b |
| Total Rating: 4.17 = (6.56 * A) + (3.26 * B) + (6.72 * C) + (1.05 * D) |
ValueRay F-Score (Strict, 0-100) 47.86
| 1. Piotroski 7.0pt |
| 2. FCF Yield 2.78% |
| 3. FCF Margin 20.67% |
| 4. Debt/Equity 0.33 |
| 5. Debt/Ebitda 2.23 |
| 6. ROIC - WACC (= -2.93)% |
| 7. RoE 6.88% |
| 8. Rev. Trend -78.80% |
| 9. EPS Trend -73.86% |
What is the price of DHR shares?
Over the past week, the price has changed by +0.94%, over one month by +7.77%, over three months by +14.11% and over the past year by -3.51%.
Is DHR a buy, sell or hold?
- Strong Buy: 19
- Buy: 4
- Hold: 3
- Sell: 0
- Strong Sell: 0
What are the forecasts/targets for the DHR price?
| Issuer | Target | Up/Down from current |
|---|---|---|
| Wallstreet Target Price | 254.2 | 12.4% |
| Analysts Target Price | 254.2 | 12.4% |
| ValueRay Target Price | 226.9 | 0.3% |
DHR Fundamental Data Overview November 27, 2025
P/E Trailing = 47.386
P/E Forward = 26.5252
P/S = 6.8091
P/B = 3.1393
P/EG = 1.9642
Beta = 0.928
Revenue TTM = 24.27b USD
EBIT TTM = 4.45b USD
EBITDA TTM = 6.87b USD
Long Term Debt = 16.83b USD (from longTermDebt, last quarter)
Short Term Debt = 23.0m USD (from shortTermDebt, last quarter)
Debt = 16.86b USD (from shortLongTermDebtTotal, last quarter)
Net Debt = 15.33b USD (from netDebt column, last quarter)
Enterprise Value = 180.57b USD (165.24b + Debt 16.86b - CCE 1.53b)
Interest Coverage Ratio = 16.41 (Ebit TTM 4.45b / Interest Expense TTM 271.0m)
FCF Yield = 2.78% (FCF TTM 5.02b / Enterprise Value 180.57b)
FCF Margin = 20.67% (FCF TTM 5.02b / Revenue TTM 24.27b)
Net Margin = 14.43% (Net Income TTM 3.50b / Revenue TTM 24.27b)
Gross Margin = 61.37% ((Revenue TTM 24.27b - Cost of Revenue TTM 9.37b) / Revenue TTM)
Gross Margin QoQ = 58.20% (prev 66.63%)
Tobins Q-Ratio = 2.26 (Enterprise Value 180.57b / Total Assets 79.90b)
Interest Expense / Debt = 0.40% (Interest Expense 67.0m / Debt 16.86b)
Taxrate = 15.61% (168.0m / 1.08b)
NOPAT = 3.75b (EBIT 4.45b * (1 - 15.61%))
Current Ratio = 1.52 (Total Current Assets 9.61b / Total Current Liabilities 6.32b)
Debt / Equity = 0.33 (Debt 16.86b / totalStockholderEquity, last quarter 51.07b)
Debt / EBITDA = 2.23 (Net Debt 15.33b / EBITDA 6.87b)
Debt / FCF = 3.06 (Net Debt 15.33b / FCF TTM 5.02b)
Total Stockholder Equity = 50.95b (last 4 quarters mean from totalStockholderEquity)
RoA = 4.38% (Net Income 3.50b / Total Assets 79.90b)
RoE = 6.88% (Net Income TTM 3.50b / Total Stockholder Equity 50.95b)
RoCE = 6.56% (EBIT 4.45b / Capital Employed (Equity 50.95b + L.T.Debt 16.83b))
RoIC = 5.55% (NOPAT 3.75b / Invested Capital 67.62b)
WACC = 8.48% (E(165.24b)/V(182.10b) * Re(9.31%) + D(16.86b)/V(182.10b) * Rd(0.40%) * (1-Tc(0.16)))
Discount Rate = 9.31% (= CAPM, Blume Beta Adj.)
Shares Correlation 3-Years: -100.0 | Cagr: -2.20%
[DCF Debug] Terminal Value 72.89% ; FCFE base≈5.01b ; Y1≈4.76b ; Y5≈4.56b
Fair Price DCF = 92.59 (DCF Value 65.40b / Shares Outstanding 706.3m; 5y FCF grow -6.55% → 3.0% )
EPS Correlation: -73.86 | EPS CAGR: -8.98% | SUE: 0.80 | # QB: 0
Revenue Correlation: -78.80 | Revenue CAGR: -7.62% | SUE: 0.11 | # QB: 0
EPS next Quarter (2026-03-31): EPS=2.00 | Chg30d=-0.026 | Revisions Net=-2 | Analysts=15
EPS next Year (2026-12-31): EPS=8.42 | Chg30d=-0.097 | Revisions Net=-18 | Growth EPS=+9.1% | Growth Revenue=+4.0%
Additional Sources for DHR Stock
Tweets: X | Stocktwits
Fund Manager Positions: Dataroma | Stockcircle